跳至主要内容
临床试验/NCT02012049
NCT02012049已完成1 期

Bioequivalence Test for Risperdal OD Tab. 2mg of Janssen Korea

Janssen Korea, Ltd., Korea0 个研究点目标入组 36 人开始时间: 2009年8月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
36
主要终点
Plasma concentrations of Risperidone

研究概览

简要总结

The purpose of this study was to conduct the bioequivalence (biological equivalence of two preparations of a drug) test in healthy adults with "Risperdal OD Tab. 2mg" of Janssen Korea as the investigational drug and "Risperdal Quicklet Tab. 2mg" as the control drug.

详细描述

This was a randomized (the study drug is assigned by chance) and open labeled (all people know the identity of the intervention) study. All participants were hospitalized in research rooms and were subsequently restricted in exercise, eating, drinking, smoking and xanthine-beverages until the end of blood collection. Water was allowed to be taken until one hour before drug administration. Participants were randomly assigned into two groups, one group receiving Risperdal OD (investigational drug), and one group receiving Risperdal Quicklet (control drug). On the day of testing, blood was collected from all participants to provide baseline measurements. Subsequently, the study drug was orally administered to the participants, followed by blood collection of a total of 13 time points, up to 24 hours. After the blood collection was finished, participants were discharged after receiving proper guidance and being examined by a psychologist. Following a wash-out period (period when receiving no intervention) of one week, participants were hospitalized once more and crossed over to receive the study drugs following the same procedure above described. The approximate study duration (including the drug administration days and wash-out period) was approximately 10 days.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
None

入排标准

年龄范围
20 Years 至 55 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Healthy Korean participants weighing more than 50kg and within 20% normal lean body weight (standard weight)
  • Participant without congenital or chronic diseases and with no symptoms or findings as a result of internal examination
  • Participant who was deemed appropriate as a result of inquiry, blood pressure, physical examination, electrocardiogram, blood and urinalysis, etc., within 28 days prior to the first administration of the investigational drug according to the protocol
  • Female participant who was confirmed as non-pregnant through urine test during health examination

排除标准

  • Participant who had a history of disease related to cardiac, respiratory, hepatic, renal, gastrointestinal or nervous system, or cardiac infarction, stroke, hypertension, arrhythmia, coronary artery disease, or neuropsychiatric diseases that could affect drug absorption, distribution, metabolism and excretion or could be risk factors when taking drugs used for the clinical trial, a history of gastrointestinal surgery except appendectomy or herniotomy, or who currently had abnormality in inquiry or physical examination
  • Participant who showed symptoms that were suspected as acute disease within 14 days from the first administration of the investigational drug
  • Participant with allergic disease requiring treatment
  • Participant who had a history of being hypersensitive to drugs or food
  • Patient who had hepatitis B antigen or who showed hepatitis C positive antigen

研究组 & 干预措施

Risperdal OD / Risperdal Quicklet

Experimental

Risperdal OD (investigational drug) + Risperdal Quicklet (control drug)

干预措施: Risperdal OD Tab. 2mg (Drug)

Risperdal OD / Risperdal Quicklet

Experimental

Risperdal OD (investigational drug) + Risperdal Quicklet (control drug)

干预措施: Risperdal Quicklet Tab. 2mg (Drug)

Risperdal Quicklet / Risperdal OD

Experimental

Risperdal Quicklet (control drug) + Risperdal OD (investigational drug)

干预措施: Risperdal OD Tab. 2mg (Drug)

Risperdal Quicklet / Risperdal OD

Experimental

Risperdal Quicklet (control drug) + Risperdal OD (investigational drug)

干预措施: Risperdal Quicklet Tab. 2mg (Drug)

结局指标

主要结局

Plasma concentrations of Risperidone

时间窗: Up to 24 hours postdose

次要结局

  • Number of participants with adverse events as a measure of safety(Approximately 10 days)

研究者

申办方类型
Industry
责任方
Sponsor

相似试验